# BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

GINIKA INC., dba CARE-PRO PHARMACY, Pharmacy Permit No. PHY 51509;

NITAL GIRISH PATEL, Pharmacist License No. RPH 48678;

and

TUAN DUC DOAN, Pharmacist License No. RPH 54387,

**Respondents.** 

Agency Case No. 6980

OAH No. 2021020918

## **DECISION AND ORDER**

The attached Stipulated Surrender of License Order is hereby adopted by the Board of

Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on February 24, 2022.

It is so ORDERED on January 25, 2022.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

eung

Seung W. Oh, Pharm.D. Board President

1	ROB BONTA	
2	Attorney General of California MARICHELLE S. TAHIMIC	
3	Supervising Deputy Attorney General LAURO A. PAREDES	
4	Deputy Attorney General State Bar No. 254663	
5	600 West Broadway, Suite 1800 San Diego, CA 92101 P.O. Box 85266	
6	San Diego, CA 92186-5266 Telephone: (619) 738-9439	
7	Facsimile: (619) 645-2061 Attorneys for Complainant	
8	Anorneys for Complainant	
9	BEFOR	
10	BOARD OF F DEPARTMENT OF C	ONSUMER AFFAIRS
11	STATE OF C.	ALIFORNIA
12	In the Matter of the Accusation Against:	Case No. 6980
13	GINIKA INC.,	OAH No. 2021020918
14	DBA CARE-PRO PHARMACY 1307 W. Sixth Street, Suite 107	STIPULATED SURRENDER OF
15	Corona, CA 92882	LICENSE AND ORDER FOR GINIKA INC., DBA CARE-PRO PHARMACY
16	Permit Number No. 51509,	ONLY
17	NITAL GIRISH PATEL 1220 Teroro Way	
18	Corona, CA 91719	
19	Pharmacist License No. RPH 48678,	
20	and	
21	TUAN DUC DOAN 2531 E. Riles Circle	
22	Anaheim, CA 92806	
23	Pharmacist License No. RPH 54387	
24	Respondents.	
25		
26		EED by and between the parties to the above-
27	entitled proceedings that the following matters are	e true:
28		
		1
	Stipulated Surrender of License GINIKA D	$VC' DBA CARE_{PRO PHARMACY}$ (Case No. 6980)

1	PARTIES
2	1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3	(Board). She brought this action solely in her official capacity and is represented in this matter by
4	Rob Bonta, Attorney General of the State of California, by Lauro A. Paredes, Deputy Attorney
5	General.
6	2. Ginika Inc., dba Care-Pro Pharmacy (Respondent) is represented in this proceeding
7	by attorney Lucy S. McAllister, whose address is: 255 N. Market Street, Suite 100, San Jose, CA
8	95110.
9	3. On or about August 2, 2013, the Board issued Pharmacy Permit Number PHY 51509
10	to Ginika Inc., dba Care-Pro Pharmacy. The Pharmacy Permit was in full force and effect at all
11	times relevant to the charges brought herein and will expire on August 1, 2021. Since August 2,
12	2013, Nital Girish Patel has been the Chief Executive Officer, Director and owner of fifty percent
13	of the outstanding stock of Ginika Inc. Since August 2, 2013, Tuan Duc Doan has been the
14	Secretary and owner of fifty percent of the outstanding stock of Ginika Inc. and the Pharmacist-
15	in-Charge of Care-Pro Pharmacy.
16	JURISDICTION
17	4. Accusation No. 6980 was filed before the Board, and is currently pending against
18	Respondent. The Accusation and all other statutorily required documents were properly served
19	on Respondent on October 12, 2020. Respondent timely filed its Notice of Defense contesting
20	the Accusation. A copy of Accusation No. 6980 is attached as Exhibit A and incorporated by
21	reference.
22	ADVISEMENT AND WAIVERS
23	5. Respondent has carefully read, fully discussed with counsel, and understands the
24	charges and allegations in Accusation No. 6980. Respondent also has carefully read, fully
25	discussed with counsel, and understands the effects of this Stipulated Surrender of License and
26	Order.
27	6. Respondent is fully aware of its legal rights in this matter, including the right to a
28	hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
	2
	Stipulated Surrender of License GINIKA INC ' DBA CARE-PRO PHARMACY (Case No. 6980)

the witnesses against them; the right to present evidence and to testify on its own behalf; the right 1 2 to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other 3 rights accorded by the California Administrative Procedure Act and other applicable laws. 4 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and 5 every right set forth above. 6 **CULPABILITY** 7 8. Respondent admits the truth of each and every charge and allegation in Accusation 8 9 No. 6980, agrees that cause exists for discipline and hereby surrenders its Pharmacy Permit Number 51509 for the Board's formal acceptance. 10 9. Respondent understands that by signing this stipulation it enables the Board to issue 11 an order accepting the surrender of its Pharmacy Permit Number 51509 without further process. 12 **CONTINGENCY** 13 10. This stipulation shall be subject to approval by the Board. Respondent understands 14 and agrees that counsel for Complainant and the staff of the Board may communicate directly 15 with the Board regarding this stipulation and surrender, without notice to or participation by 16 Respondent or its counsel. By signing the stipulation, Respondent understands and agrees that it 17 may not withdraw its agreement or seek to rescind the stipulation prior to the time the Board 18 19 considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Surrender and Disciplinary Order shall be of no force or effect, except for this 20paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not 21 be disqualified from further action by having considered this matter. 22 The parties understand and agree that Portable Document Format (PDF) and facsimile 11. 23 24 copies of this Stipulated Surrender of License and Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals. 25 12. This Stipulated Surrender of License and Order is intended by the parties to be an 26 integrated writing representing the complete, final, and exclusive embodiment of their agreement. 27 It supersedes any and all prior or contemporaneous agreements, understandings, discussions, 28 3

negotiations, and commitments (written or oral). This Stipulated Surrender of License and Order
 may not be altered, amended, modified, supplemented, or otherwise changed except by a writing
 executed by an authorized representative of each of the parties.

13. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Order:

#### **ORDER**

IT IS HEREBY ORDERED that Pharmacy Permit No. PHY 51509 issued to Respondent
Ginika Inc., dba Care-Pro Pharmacy, dba Care-Pro Pharmacy, Nital Girish Patel, Shareholder,
Tuan Duc Doan, Shareholder, is surrendered and accepted by the Board. However, the surrender
will be stayed for a period of 90 days from the effective date, by which time the pharmacy shall
be sold or closed. In addition, upon signature of the stipulated settlement Respondent Pharmacy
shall designate a new Pharmacist-in-Charge within 14 days.

1. In the event that the Pharmacy is not sold within the ninety-day period upon the 13 14 effective date of decision Respondent Doan shall, within ten (10) days of the stayed 90 days of the effective date of this decision, arrange for the destruction of, the transfer to, sale of or storage 15 in a facility licensed and approved by the Board of all controlled substances and dangerous drugs 16 and/or dangerous devices. Respondent Doan, shall further arrange for the transfer of all records of 17 acquisition and disposition of dangerous drugs to premises licensed and approved by the Board. 18 Respondent Doan, shall further provide written proof of such disposition and submit a completed 19 Discontinuance of Business form according to Board guidelines. 20

During the ninety-day stay, Respondent Pharmacy shall retain an independent
 consultant at its own expense who shall be responsible for conducting an inspection to review the
 operations of Respondent Pharmacy on a bi-monthly (twice-a-month) basis for compliance by
 Respondent Pharmacy with state and federal laws and regulations governing the practice of
 pharmacy, and compliance by respondent. During the stay period, the Board or its designee,
 retains the discretion to modify the frequency of the inspection of the pharmacist consultant's
 review.

28

4

5

The consultant shall be a pharmacist licensed by and not on probation with the Board and whose name shall be submitted to the Board or its designee, for prior approval, within ten (10) days of the effective date of this decision.

Failure to timely retain, seek approval of, or ensure timely reporting by the consultant shall be considered a violation.

3. In the event that Respondent Pharmacy is not sold within the ninety-day period upon 6 the effective date of decision, Respondent Doan, shall within ten (10) days of the stayed 90 days 7 8 of the effective date of this decision, arrange for the continuation of care for ongoing patients of 9 the pharmacy by, at minimum, providing a written notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that identifies one or more area pharmacies capable 10 of taking up the patients' care, and by cooperating as may be necessary in the transfer of records 11 or prescriptions for ongoing patients. Within five days of its provision to the pharmacy's ongoing 12 patients, Respondent Doan, shall provide a copy of the written notice to the Board. For the 13 14 purposes of this provision, "ongoing patients" means those patients for whom the pharmacy has on file a prescription with one or more refills outstanding, or for whom the pharmacy has filled a 15 prescription within the preceding ninety (90) days. 16

17

18

19

1

2

3

4

5

4. The surrender of the Pharmacy License by the Board shall constitute the imposition of discipline. This stipulation constitutes a record of the discipline and shall become a part of Respondents Doan and Patel's, license history with the Board of Pharmacy.

20 5. Respondent Pharmacy shall lose all rights and privileges as a Pharmacy in California
21 as of the effective date of the Board's Decision and Order.

6. Respondents Doan and Patel understand and agree that if they ever file an application
for licensure or a licensed premises or a petition for reinstatement in the State of California, the
Board shall treat it as a new application for licensure.

7. Respondent Pharmacy may not reapply for any license from the Board for three (3)
years from the effective date of this decision. Respondent stipulates that should they apply for any
license from the Board on or after the effective date of this decision, all allegations set forth in the
Accusation No. 6980 shall be deemed to be true, correct and admitted by Respondents when the

1	Board determines whether to grant or deny the application. Respondent shall satisfy all
2	requirements applicable to that license as of the date the application is submitted to the Board,
3	including, but not limited to, taking and passing licensing examination(s) as well as fulfilling any
4	education or experience requirements prior to the issuance of a new license.
5	8. Respondent Pharmacy shall relinquish its pharmacy permit, including any indicia of
6	licensure issued by the Board, within ten (10) days of the stayed 90 days of the effective date of
7	this decision. Respondent shall relinquish the premises wall license and renewal license to the
8	Board within ten (10) days of the stayed 90 days of the effective date of this decision.
9	ACCEPTANCE
10	I have carefully read the above Stipulated Surrender of License and Order and have fully
11	discussed it with my attorney Lucy S. McAllister. I understand the stipulation and the effect it
12	will have on my Pharmacy Permit. I enter into this Stipulated Surrender of License and Order
13	voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
14	Board of Pharmacy.
15	
16	DATED:
17	NITAL GIRISH PATEL CHIEF EXECUTIVE OFFICER/DIRECTOR
18	AND OWNER GINIKA INC., DBA CARE-PRO
19	PHARMACY
20	
21	
22	DATED:
23	TUAN DUC DOAN
24	SECRETARY AND OWNER GINIKA INC., DBA CARE-PRO
25	PHARMACY
26	
27	
28	
	6
	Stipulated Surrender of License GINIKA INC ' DBA CARE-PRO PHARMACY (Case No. 6980)

Stipulated Surrender of License GINIKA INC.' DBA CARE-PRO PHARMACY (Case No. 6980)

Board determines whether to grant or deny the application. Respondent shall satisfy all
 requirements applicable to that license as of the date the application is submitted to the Board,
 including, but not limited to, taking and passing licensing examination(s) as well as fulfilling any
 education or experience requirements prior to the issuance of a new license.

8. Respondent Pharmacy shall relinquish its pharmacy permit, including any indicia of
licensure issued by the Board, within ten (10) days of the stayed 90 days of the effective date of
this decision. Respondent shall relinquish the premises wall license and renewal license to the
Board within ten (10) days of the stayed 90 days of the effective date of this decision.

DATED:

DATED:

#### ACCEPTANCE

I have carefully read the above Stipulated Surrender of License and Order and have fully
discussed it with my attorney Lucy S. McAllister. I understand the stipulation and the effect it
will have on my Pharmacy Permit. I enter into this Stipulated Surrender of License and Order
voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
Board of Pharmacy.

10/5/2021WHAWNITAL GIRISH PATEL<br/>CHIEF EXECUTIVE OFFICER/DIRECTOR<br/>AND OWNER<br/>GINIKA INC., DBA CARE-PRO<br/>PHARMACY10/6/2021JumbTUAN DUC DOAN<br/>SECRETARY AND OWNER<br/>GINIKA INC., DBA CARE-PRO<br/>PHARMACY

1	I have read and fully discussed with Respondent Ginika Inc., dba Care-Pro Pharmacy the
2	terms and conditions and other matters contained in this Stipulated Surrender of License and
3	Order. I approve its form and content.
4	
5	DATED: LUCY S. MCALLISTER
6	Attorney for Respondent
7	
8	<u>ENDORSEMENT</u>
9	The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted
10	for consideration by the Board of Pharmacy of the Department of Consumer Affairs.
11	DATED: Respectfully submitted,
12	ROB BONTA
13	Attorney General of California MARICHELLE S. TAHIMIC
14	Supervising Deputy Attorney General
15	
16	LAURO A. PAREDES Deputy Attorney General
17	Attorneys for Complainant
18	
19	SD2020800445
20	83074273
21	
22	
23	
24	
25 26	
26 27	
27	
28	
	7 Stinulated Surrander of License CINIKA INC ' DBA CARE BRO BHARMACY (Cose No. 6080)

1	I have read and fully discussed with Respondent Ginika Inc., dba Care-Pro Pharm	acy the
2	terms and conditions and other matters contained in this Stipulated Surrender of Licens	e and
3	3 Order. I approve its form and content.	
4	4 10/6/2021 Ruey Mellester	
5	5 DATED:	
6	5 LUCY S. MCALLISTER Attorney for Respondent	
7	7	
8	B ENDORSEMENT	
9	The foregoing Stipulated Surrender of License and Order is hereby respectfully su	ıbmitted
10		
11	DATED: Respectfully submitted,	
12	ROB BONTA	
13	MARICHELLE S. I AHIMIC	1
14	4 Supervising Deputy Attorney Gen	erai
15		
16	Deputy Attorney General	
17	7 Attorneys for Complainant	
18		
19	SD2020800445	
20		
21		
22		
23		
24		
25		
26	김 씨는 것은 것은 것 같은 것 같은 것 같은 것은 것은 것을 많은 것이 없는 것이 없다. 것 같은 것은 것 같은 것 같은 것 같은 것 같은 것 같은 것 같은	
27		
28		
	7	

### Exhibit A

Accusation No. 6980

1 2	XAVIER BECERRA Attorney General of California THEODORE S. DRCAR Supervising Deputy Attorney General	
3	DESIREE I. KELLOGG Deputy Attorney General	
4	State Bar No. 126461	
5	600 West Broadway, Suite 1800 San Diego, CA 92101 P.O. Box 85266	
6	San Diego, CA 92186-5266	
7	Telephone: (619) 738-9429 Facsimile: (619) 645-2061	
8	Attorneys for Complainant	
9	BEFOR	
10	BOARD OF F DEPARTMENT OF C	ONSUMER AFFAIRS
11	STATE OF C.	ALIFORNIA
12		
13	In the Matter of the Accusation Against:	Case No. 6980
14	GINIKA INC. DBA CARE-PRO PHARMACY,	
15 16	NITAL GIRISH PATEL AND TUAN DUC DOAN OWNERS, DIRECTORS AND/OR OFFICERS	ACCUSATION
17	1307 W. Sixth Street, Suite 107 Corona, CA 92882	
18	Pharmacy Permit No. PHY 51509,	
19	NITAL GIRISH PATEL	
20	1220 Teroro Way Corona, CA 91719	
21	Pharmacist License No. RPH 48678,	
22	and	
23	TUAN DUC DOAN 2531 E. Riles Circle	
24	Anaheim, CA 92806	
25	Pharmacist License No. RPH 54387	
26	Respondents.	
27		
28		
	(GINIKA INC., DBA CARE-PRO PHARMA	ACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

1	PARTIES
2	1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
3	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.
4	2. On or about August 2, 2013, the Board of Pharmacy issued Pharmacy Permit Number
5	PHY 51509 to Ginika Inc., dba Care-Pro Pharmacy (Care-Pro Pharmacy). The Pharmacy Permit
6	was in full force and effect at all times relevant to the charges brought herein and will expire on
7	August 1, 2021. Since August 2, 2013, Nital Girish Patel has been the Chief Executive Officer,
8	Director and owner of fifty percent of the outstanding stock of Ginika Inc. Since August 2, 2013,
9	Tuan Duc Doan has been the Secretary and owner of fifty percent of the outstanding stock of
10	Ginika Inc. and the Pharmacist-in-Charge of Care-Pro Pharmacy.
11	3. On or about May 9, 1996, the Board of Pharmacy issued Pharmacist License Number
12	RPH 48678 to Nital Girish Patel. The Pharmacist License was in full force and effect at all times
13	relevant to the charges brought herein and will expire on July 31, 2021, unless renewed.
14	4. On or about March 24, 2003, the Board of Pharmacy issued Pharmacist License
15	Number RPH 54387 to Tuan Duc Doan. The Pharmacist License was in full force and effect at
16	all times relevant to the charges brought herein and will expire on July 31, 2022, unless renewed.
17	JURISDICTION
18	5. This Accusation is brought before the Board of Pharmacy (Board), Department of
19	Consumer Affairs, under the authority of the following laws. All section references are to the
20	Business and Professions Code (Code) unless otherwise indicated.
21	6. Section 4011 of the Code provides that the Board shall administer and enforce both
22	the Pharmacy Law (Bus. & Prof. Code, § 4000 et seq.) and the Uniform Controlled Substances
23	Act (Health & Safety Code, § 11000 et seq.).
24	7. Code section 4300, subdivision (a) provides that every license issued by the Board
25	may be suspended or revoked.
26	///
27	///
28	///
	2 (GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN)
	ACCUSATION

1	8. Code section 4300.1 states:
2	The expiration, cancellation, forfeiture, or suspension of a board-issued license
3	by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any
4	licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revolving the license.
5	a decision suspending or revoking the license.
6	STATUTORY PROVISIONS
7	9. Code section 4022 states:
8 9	"Dangerous drug" or "dangerous device" means any drug or device unsafe for self-use in humans or animals, and includes the following:
10	(a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without prescription," "Rx only," or words of similar import.
11	(b) Any device that bears the statement: "Caution: federal law restricts this device to sale by or on the order of a ""Px only" or words of similar import
12	device to sale by or on the order of a" "Rx only," or words of similar import, the blank to be filled in with the designation of the practitioner licensed to use or order use of the device.
13 14	(c) Any other drug or device that by federal or state law can be lawfully dispensed only on prescription or furnished pursuant to Section 4006.
15	10. Code section 4113, subdivision (c) states:
16 17	The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.
18	11. Code section 4301 states in pertinent part:
19	The board shall take action against any holder of a license who is guilty of
20	unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:
21	not minted to, uny of the following.
22	(j) The violation of any of the statutes of this state, or any other state, or of the
23	United States regulating controlled substances and dangerous drugs
24	
25	(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter
26	or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or any other state or federal regulatory
27	agency.
28	
	3
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

1	12. Code section 4306.5, subdivisions (a) and (b) states:
2	Unprofessional conduct for a pharmacist may include any of the following:
3	(a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or her education, training, or experience as a pharmacist, whether or
4	not the act or omission arises in the course of the practice of pharmacy or the ownership, management, administration, or operation of a pharmacy or other entity
5	licensed by the board.
6	(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with
7	regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the provision of services.
8	
9	
10	13. Code section 4307, subdivision (a) states:
11	Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was
12	under suspension, or who has been a manager, administrator, owner member, officer, director, associate, or partner of any partnership, corporation, firm, or association
13	whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manger, administrator, owner,
14	member, officer, director, associate, or partner had knowledge or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manger, administrator,
15	owner, member, officer, director, associate, or partner of a licensee as follows:
16 17	(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
18 19	(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.
20	14. Health and Safety Code section 11153, subdivision (a), states:
21	A prescription for a controlled substance shall only be issued for a legitimate
22	medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding
23	controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order
24	purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or
25	habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the
26 27	purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use.
28	///
	4 (GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN)
	(GINIKA INC., DDA CARE-I KOTHARMACT, NITAL GIRISHTATEL, and TOAN DOC DOAN) ACCUSATION

1	15. Health and Safety Code section 11162.1, subdivision (a) states:
2 3	(a) The prescription forms for controlled substances shall be printed with the following features:
4	(1) A latent, repetitive 'void' pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word "void" shall appear in a pattern across the entire front of the prescription.
5 6	(2) A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words "California Security Prescription."
7	(3) A chemical void protection that prevents alteration by chemical washing.
8	(4) A feature printed in thermochromic ink.
9	(5) An area of opaque writing so that the writing disappears if the prescription is lightened.
10	(6) A description of the security features included on each prescription form.
11	(7) (A) Six quantity check off boxes shall be printed on the form so that the
12 13	prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
13	1-24
15	25-49
16	50-74
17	75-100
18	101-150
19	151 and over.
20	(b) In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
21	(8) Prescription blanks shall contain a statement printed on the bottom of the
22	prescription blank that the "Prescription is void if the number of drugs prescribed is not noted."
23 24	(9) The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
25	(10) Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
26	(11) The date of origin of the prescription.
27	(12) A check box indicating the prescriber's order not to substitute.
28	5
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

1	(13) An identifying number assigned to the approved security printer by the Department of Justice.
2	(14) (A) A check box by the name of each prescriber when a prescription form
3	lists multiple prescribers.
4	(B) Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
5	(b) Each batch of controlled substance prescription forms shall have the lot
6 7	number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
8	
9	16. Health and Safety Code section 11164 states:
10	Except as provided in Section 11167, no person shall prescribe a controlled
11	substance, nor shall any person fill, compound, or dispense a prescription for a controlled substance, unless it complies with the requirements of this section.
12	(a) Each prescription for a controlled substance classified in Schedule II, III, IV, or V, except as authorized by subdivision (b), shall be made on a controlled
13	substance prescription form as specified in Section 11162.1 and shall meet the following requirements:
14	(1) The prescription shall be signed and dated by the prescriber in ink and
15 16	shall contain the prescriber's address and telephone number; the name of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services; refill
17	information, such as the number of refills ordered and whether the prescription is a first-time request or a refill; and the name, quantity, strength, and directions for use of the controlled substance prescribed.
18	(2) The prescription shall also contain the address of the person for whom
19	the controlled substance is prescribed. If the prescriber does not specify this address on the prescription, the pharmacist filling the prescription or an employee
20 21	acting under the direction of the pharmacist shall write or type the address on the prescription or maintain this information in a readily retrievable form in the pharmacy.
22	
23	<b>REGULATORY PROVISIONS</b>
24	17. Code of Federal Regulations, Title 21, section 1306.04, subdivision (a), states:
25	A prescription for a controlled substance to be effective must be issued for a
26	legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing
27	of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. An order
28	purporting to be a prescription issued not in the usual course of professional treatment or in legitimate and authorized research is not a prescription within the meaning and
	6
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

ĺ	
1 2	intent of section 309 of the Act (21 U.S.C. 829) and the person knowingly filling such a purported prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.
3	18. California Code of Regulations, title 16, section 1761 states:
4	(a) No pharmacist shall compound or dispense any prescription which contains
5	any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
6 7	
7 8	(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose.
9	medicai purpose.
10	<u>COST RECOVERY</u>
11	19. Section 125.3 of the Code provides, in pertinent part, that the Board may request the
12	administrative law judge to direct a licentiate found to have committed a violation or violations of
13	the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
14	enforcement of the case.
15	DRUGS
16	20. <u>Phenergan with Codeine</u> is the brand name for promethazine with codeine, a
17	Schedule V controlled substance pursuant to Health and Safety Code section 11058, subdivision
18	(c)(1), and is a dangerous drug as defined by Business and Professions Code section 4022.
19	21. <u>Roxicodone</u> is the brand name for oxycodone, a Schedule II controlled substance
20	pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M) and a dangerous drug as
21	defined by Business and Professions Code section 4022.
22	FACTUAL ALLEGATIONS
23	22. At all relevant times, Respondent Care-Pro Pharmacy was an independent community
24	pharmacy located in Corona, California. At all relevant times, Respondent Doan was the
25	Pharmacist-in-Charge and Respondent Patel was a staff pharmacist. Both of them were the
26	owners of Respondent Care-Pro Pharmacy (collectively Respondents).
27	23. On May 29, 2015, Doan, on behalf of Care-Pro Pharmacy, certified under penalty of
28	perjury under the laws of the State of California that pharmacists at Care-Pro Pharmacy were 7
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

aware of their corresponding responsibility to determine that a prescription written for a 1 2 controlled substance was issued for legitimate medical purposes only. He also verified that he was aware that a pharmacist must not dispense a controlled substance prescription if he knew or 3 had objective reason to know that the prescription was not issued for a legitimate medical purpose 4 5 and all written controlled substances prescriptions (with limited exceptions) dispensed by Care-Pro Pharmacy were on California Security Prescription forms. He also verified that before 6 7 dispensing a prescription with a significant irregularity or error, pharmacists should contact the prescriber to obtain information needed to validate the prescription. 8

9 24. A Board of Pharmacy inspector conducted an inspection of Care-Pro Pharmacy.
10 Respondents Doan and Patel were present during the inspection. Based on the facts set forth
11 below, her educational and professional background and knowledge of pharmacy and drug laws,
12 the Board's inspector determined that on numerous occasions, Respondents failed to exercise
13 their corresponding responsibility and best professional judgment to dispense only controlled
14 substance prescriptions issued for legitimate medical purposes.

25. The inspector focused on three prescribers, Dr. R.G., Dr. J.B. and Physician Assistant 15 (PA) J.E. The inspector found those prescribers' prescriptions contained significant irregularities 16 and "red flags," suggesting that prescriptions were not written or filled for a legitimate medical 17 purpose. Respondents' prescribing profiles for these physicians indicated that promethazine with 18 codeine and/or oxycodone 30mg immediate-release, drugs associated with high rates of abuse and 19 diversion, were the most commonly prescribed drugs for these prescribers. Most, if not all of the 20prescriptions from these prescribers exhibited obvious red flags of drug abuse that Respondents 21 ignored when filling them, in spite of the Respondents' corresponding responsibility to ensure 22 that all prescriptions dispensed were for a legitimate medical purpose. 23 24 Those red flags included: • Irregularities on the face of the prescriptions; 25 • Cash payments; 26

• Prescriptions written for an unusually large quantity of drugs;

27

- The same combinations of drugs prescribed for multiple patients;
  - 8

• Initial prescriptions written for strong opiates; 1 2 • Prescriptions written on non-compliant controlled substance prescription forms; • Long distances traveled from the patient's home to the prescriber's office or 3 pharmacy. 4 26. From July 1, 2016 through August 22, 2019, Respondents dispensed 318 5 prescriptions for controlled substances under the prescribing authority of Dr. R.G., Dr. J.B. and 6 7 PA J.E., 145 of those prescriptions were dispensed based on prescription forms that were not 8 compliant with the requirements of the Health and Safety Code. 9 27. In connection with the aforementioned prescriptions, Respondents dispensed an aggregate total of 25,627 tablets of oxycodone immediate-release 30mg, 180 tablets of 10 oxycodone immediate-release 20mg and **37,666 mL** of promethazine with codeine. 11 28. Respondents dispensed controlled substances without ensuring they were for a 12 legitimate medical use when obvious, objective, and systemic signs of irregularities and red flags 13 14 of illegitimacy existed as described below. 29. Respondents dispensed controlled substances even though customers paid for almost 15 all of the 318 medications in cash even though pharmacists know that almost all patients seek 16 reimbursement from insurance companies or government agencies for medications. 17 30. In many instances, Respondents charged more than the fair market value for 150 18 19 tablets of oxycodone 30mg and 1 pint of promethazine with codeine, allegedly prescribed by Dr. R.G., Dr. J.B. and PA J.E. Namely, Respondents charged customers \$890.60 for 150 tablets of 20Oxycodone 30mg and \$140.00 for 1 pint of promethazine with codeine when neighboring 21 pharmacies charged \$244.99, \$57.00, \$374.99 and \$538.00 for the same quantity and strength of 22 oxycodone and \$61.59, \$26.00, \$36.99 and \$59.00 for the same quantity of promethazine with 23 24 codeine. 31. Respondents filled prescriptions written by Dr. R.G. and Dr. J.B. for oxycodone and 25 promethazine with codeine even though it is uncommon for family practitioners to prescribe those 26 controlled substances. Respondents could have reviewed the Medical Board website and 27 concluded that Dr. R.G. reported his primary area of practice as family medicine with emergency 28 (GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN)

ACCUSATION

and internal medicine as his secondary practices on the Medical Board website while Dr. J.B.
 reported his primary area of practice as family medicine and geriatric medicine as his secondary
 area of practice.

32. An unusually high percentage, approximately half of the prescriptions that 4 5 Respondents filled from prescriptions issued by Dr. R.G. and Dr. J.B. were for a drug of high potential for diversion and drug abuse, oxycodone 30mg immediate-release in the highest strength 6 7 available, and for the unusually high quantity of 150 tablets, to multiple customers. Many of Respondents' customers with prescriptions from these doctors were dispensed the highest 8 9 strength of oxycodone as a starting dose even though it is not recommended to prescribe the highest strength to opioid naïve patients. Eight of the same customers were dispensed 10 prescriptions for the same controlled substance, oxycodone 30mg from both Dr. R.G. and J.B. 11 around the period, indicating that those customers may have been "doctor shopping." 12

33. An unusually high percentage, approximately one third of the prescriptions that 13 Respondents filled from prescriptions issued by PA J.E., were for a drug of high potential for 14 diversion and drug abuse, promethazine with codeine, written for the unusually large quantity of 15 473 mL (one pint), to multiple patients. Respondents filled sixteen of PA J.E.'s prescriptions for 16 both oxycodone 30mg and promethazine with codeine even though a pharmacist knows that those 17 drugs have the duplicative effect on a patient and they are both controlled substances that are 18 addictive and prone to abuse. Similarly, Respondents dispensed PA J.E.'s prescriptions for two 19 antihistamines, promethazine with codeine and loratadine at the same time; pharmacists know 20 that is irregular to prescribe two antihistamines concurrently because it increases the side effects 21 of those drugs. Respondents also dispensed three of PA J.E.'s prescriptions for promethazine with 22 codeine 17, 72 and 79 days after issuance of the prescriptions even though patients with 23 24 respiratory infections would immediately fill their prescriptions for their acute condition. Respondents dispensed oxycodone to opioid naïve patients from PA J.E.'s prescriptions in the 25 highest or second highest strength (30mg and 20mg) available even though such a practice is 26 medically not recommended. 27

28

///

1	34. Respondents filled prescriptions even though certain customers' addresses on
2	prescriptions or identification cards were located many miles away from Care-Pro Pharmacy.
3	Likewise, Dr. R.G.'s, Dr. J.B.'s and P.A. J.E.'s offices were also located far from Care-Pro
4	Pharmacy (Dr. R.G.'s offices were 22 and 47 miles away from Care-Pro Pharmacy, Dr. J.B.'s
5	office was 47 miles away and P.A. J.E.'s offices were 23-51 miles away). Dr. R.G.'s and Dr.
6	J.B.'s prescriptions had the same office address on them.
7	35. Respondents dispensed controlled substances despite the fact that drugs on Dr. R.G.'s
8	prescriptions were misspelled. Respondents also dispensed controlled substances when
9	customers concurrently submitted unusual documents such as doctor's progress notes and
10	diagnoses to justify the issuance of those controlled substances. Those documents contained
11	misspellings and/or listings of drugs unavailable on the market or the documents were
12	incomplete.
13	36. Respondents dispensed controlled substances even though 145 of the prescription
14	forms used by Dr. R.G. and Dr. J.B. lacked a "California Security Prescription" watermark, refill
15	checkboxes and/or a lot number.
16	37. Respondents did not resolve the red flags of illegitimacy previously described.
17	FIRST CAUSE FOR DISCIPLINE
18	(Failing to Comply with Corresponding Responsibility
19	for Controlled Substance Prescriptions Against All Respondents)
20	38. Respondents are subject to disciplinary action under Code sections 4301, subdivisions
21	(j) and (o), for violating Health and Safety Code section 11153, subdivision (a), and Code of
22	Federal Regulations, Title 21, section 1306.04, subdivision (a), because they failed to comply
23	with their corresponding responsibility to ensure that controlled substances were dispensed for a
24	legitimate medical purpose. As described above, Respondents repeatedly furnished prescriptions
25	for controlled substances even though obvious and systemic "red flags" were present to indicate
26	those prescriptions were not issued for a legitimate medical purpose.
27	///
28	///
	11
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

1	SECOND CAUSE FOR DISCIPLINE
2	(Dispensing Controlled Substance Prescriptions with Significant Errors, Omissions,
3	Irregularities, Uncertainties, Ambiguities or Alterations Against All Respondents)
4	39. Respondents are subject to disciplinary action under Code section 4301, subdivision
5	(o), for violating title 16, California Code of Regulations, sections 1761, subdivisions (a) and (b)
6	because they dispensed controlled substances based on prescriptions which contained significant
7	errors, omissions, irregularities, uncertainties, ambiguities or alterations, as described above.
8	THIRD CAUSE FOR DISCIPLINE
9	(Failing to Exercise or Implement Best Professional Judgment or Corresponding
10	<b>Responsibility when Dispensing Controlled Substances</b>
11	Against Respondents Tuan Duc Doan and Nital Girish Patel)
12	40. Respondents Tuan Duc Doan and Nital Girish Patel are subject to disciplinary action
13	under Code section 4301, subdivision (o), for violating Business and Professions Code section
14	4306.5, subdivisions (a) and (b), because they failed to exercise or implement their best
15	professional judgment or corresponding responsibility when dispensing controlled substances, as
16	described above.
17	FOURTH CAUSE FOR DISCIPLINE
18	(Dispensing Controlled Substance Prescriptions Written
19	on Unauthorized Forms Against All Respondents)
20	41. Respondents are subject to disciplinary action under Code sections 4301, subdivisions
21	(j) and (o), for violating Health and Safety Code section 11164, subdivision (a), because they
22	filled and dispensed controlled substances from prescription forms that did not comply with the
23	requirements of Health and Safety Code section 11162.1, as described above.
24	FIFTH CAUSE FOR DISCIPLINE
25	(Unprofessional Conduct against All Respondents)
26	42. Respondents are subject to disciplinary action under Code section 4301 for
27	unprofessional conduct because they engaged in the activities described above.
28	///
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

1	OTHER MATTERS
2	43. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY
3	51509 issued to Ginika Inc., doing business as Care-Pro Pharmacy, it shall be prohibited from
4	serving as a manager, administrator, owner, member, officer, director, associate, or partner of a
5	licensee for five years if Pharmacy Permit Number PHY 51509 is placed on probation or until the
6	Pharmacy Permit is reinstated if it is revoked.
7	44. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY
8	51509 issued to Ginika Inc., doing business as Care-Pro Pharmacy, while Tuan Duc Doan has
9	been an owner or manager and had knowledge of or knowingly participated in any conduct for
10	which the licensee was disciplined, he shall be prohibited from serving as a manager,
11	administrator, owner, member, officer, director, associate, or partner of a licensee for five years if
12	the Pharmacy Permit is placed on probation or until the Pharmacy Permit is reinstated, if it is
13	revoked.
14	45. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY
15	51509 issued to Ginika Inc., doing business as Care-Pro Pharmacy while Nital Girish Patel has
16	been an owner or manager and had knowledge of or knowingly participated in any conduct for
17	which the licensee was disciplined, she shall be prohibited from serving as a manager,
18	administrator, owner, member, officer, director, associate, or partner of a licensee for five years if
19	the Pharmacy Permit is placed on probation or until the Pharmacy Permit is reinstated, if it is
20	revoked.
21	46. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.
22	RPH 54387 issued to Tuan Duc Doan, he shall be prohibited from serving as a manager,
23	administrator, owner, member, officer, director, associate, or partner of a licensee for five years if
24	the Pharmacist License is placed on probation or until the Pharmacist License is reinstated, if it is
25	revoked.
26	47. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.
27	RPH 48678 issued to Nital Girish Patel, she shall be prohibited from serving as a manager,
28	administrator, owner, member, officer, director, associate, or partner of a licensee for five years if
	13 (GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION

the Pharmacist License is placed on probation or until the Pharmacist License is reinstated, if it is 1 2 revoked. **DISCIPLINARY CONSIDERATIONS** 3 48. To determine the degree of discipline, if any, to be imposed on Respondent Care-Pro 4 Pharmacy and Respondent Doan, Complainant alleges as follows. On September 7, 2017, the 5 Board issued Citation number CI 2016 72971 against Respondent Care-Pro Pharmacy and 6 Citation number CI 2017 76189 against Respondent Doan for violating California Code of 7 8 Regulations, title 16, section 1715, subdivision (a) (failing to complete a community pharmacy 9 self-assessment). The Board issued a fine against Respondent Doan, which he paid. 10 **PRAYER** WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, 11 and that following the hearing, the Board of Pharmacy issue a decision: 12 1. Revoking or suspending Pharmacy Permit Number 51509, issued to Ginika Inc., dba 13 14 Care-Pro Pharmacy; 2. Revoking or suspending Pharmacist License Number RPH 48678, issued to Nital 15 Girish Patel; 16 3. Revoking or suspending Pharmacist License Number RPH 54387, issued to Tuan Duc 17 Doan; 18 4. 19 Prohibiting Ginika Inc., dba Care-Pro Pharmacy from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if 20Pharmacy Permit Number PHY 51509 is placed on probation or until the Pharmacy Permit is 21 reinstated, if it is revoked; 22 5. Prohibiting Tuan Duc Doan from serving as a manager, administrator, owner, 23 24 member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 51509 is placed on probation or until the Pharmacy Permit is reinstated, if it is 25 revoked; 26 6. Prohibiting Nital Girish Patel from serving as a manager, administrator, owner, 27 member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit 28 14

1	Number PHY 51509 is placed on probation or until the Pharmacy Permit is reinstated, if it is
2	revoked;
3	7. Prohibiting Tuan Duc Doan from serving as a manager, administrator, owner,
4	member, officer, director, associate, or partner of a licensee for five years if Pharmacist License
5	Number RPH 54387 is placed on probation or until the Pharmacist License is reinstated, if it is
6	revoked;
7	8. Prohibiting Nital Girish Patel from serving as a manager, administrator, owner,
8	member, officer, director, associate, or partner of a licensee for five years if Pharmacist License
9	Number RPH 48678 is placed on probation or until the Pharmacist License is reinstated, if it is
10	revoked;
11	9. Ordering Ginika Inc., dba Care-Pro Pharmacy, Nital Girish Patel and Tuan Duc Doan
12	to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this
13	case, pursuant to Business and Professions Code section 125.3; and,
14	10. Taking such other and further action as deemed necessary and proper.
15	10/9/2020 Signature on File
16	DATED: Signature on File ANNE SODERGREN
17	Executive Officer Board of Pharmacy
18	Department of Consumer Affairs State of California
19	Complainant
20	
21	SD2020800445 82471683.docx
22	
23	
24	
25	
26	
27	
28	15
	(GINIKA INC., DBA CARE-PRO PHARMACY, NITAL GIRISH PATEL, and TUAN DUC DOAN) ACCUSATION